Browse our 1,000+ Publications
Latest Publications
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen, J et al.
Nature
February 2024
Authors and Affiliates
Jani Huuhtanen; Shady Adnan-Awad; Jason Theodoropoulos; Sofia Forstén; Rebecca Warfvinge; Olli Dufva; Jonas Bouhlal; Parashar Dhapola; Hanna Duàn; Essi Laajala; Tiina Kasanen; Jay Klievink; Mette Ilander; Taina Jaatinen; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Andreas Burchert; Göran Karlsson; Anna Kreutzman; Harri Lähdesmäki and Satu Mustjoki.
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case
Vallacchi V, et al.
Journal for ImmunoTherapy of Cancer
January 2024
Authors and Affiliates
Viviana Vallacchi 1, Elisabetta Vergani 1, Mara Cossa 2, Chiara Gargiuli 3, Adele Busico 4, Andrea Devecchi 4, Matteo Dugo 5, Laura Bergamaschi 1, Loris De Cecco 6, Stefano Cavalieri 7,8, Barbara Valeri 2, Elena Tamborini 4, Gianfrancesco Gallino 9, Michele Del Vecchio 7, Mario Santinami 9, Marialuisa Sensi 3, Licia Rivoltini 1, Lorenza Di Guardo 7, Monica Rodolfo 10;
1 Department of Experimental Oncology, Unit of Translational Immunology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
2 Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3 Applied Research and Technology Development Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
4 Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
5 Department of Medical Oncology, San Raffaele Hospital, Milan, Italy.
6 Integrated Biology of Rare Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
7 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
8 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
9 Melanoma Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
10 Department of Experimental Oncology, Unit of Translational Immunology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy monica.rodolfo@istitutotumori.mi.it.
ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children’s Oncology Group Study
Wistinghausen B, et al.
Blood Advances
January 2024
Authors and Affiliates
Birte Wistinghausen 1, Keri Toner 2, Donald A Barkauskas 3, Lauren P Jerkins 4, Hannah Kinoshita 5, Pamela Chansky 6, Gloria Pezzella 7, Lauren Saguilig 4, Robert J Hayashi 8, Harshal A Abhyankar 9, Brooks Scull 10, Vivekanudeep Karri 10, Jay Tanna 5, Patrick J Hanley 1, Michelle L Hermiston 11, Carl E Allen 10, Catherine M Bollard 4;
1 Children's National Medical Center, Washington, District of Columbia, United States.
2 Children's National Health System, Washington, District of Columbia, United States.
3 University of Southern California, United States.
4 Children's National Hospital, United States.
5 Childrens National Medical Center, Washington, District of Columbia, United States.
6 The George Washington University School of Medicine and Health Sciences, United States.
7 Children's National Hospital, Washington, District of Columbia, United States.
8 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
9 Baylor College Of Medicine, Houston, Texas, United States.
10 Baylor College of Medicine, Houston, Texas, United States.
11 University of California, San Francisco, San Francisco, California, United States.
Discovery of U2AF1 neoantigens in myeloid neoplasms
Biernacki MA, et al.
Journal for ImmunoTherapy of Cancer
January 2024
Authors and Affiliates
Melinda Ann Biernacki 1,2, Jessica Lok 3, Ralph Graeme Black 3, Kimberly A Foster 4, Carrie Cummings 3, Kyle B Woodward 3, Tim Monahan 3, Vivian G Oehler 3,2, Derek L Stirewalt 3,2, David Wu 5, Anthony Rongvaux 3, Hans Joachim Deeg 3,2, Marie Bleakley 3,6;
1 Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA mbiernac@fredhutch.org.
2 Department of Medicine, University of Washington, Seattle, Washington, USA.
3 Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
4 Department of Immunology, University of Washington, Seattle, Washington, USA.
5 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
6 Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy
Manzar GS, et al.
Brachytherapy
December 2023
Authors and Affiliates
Gohar S Manzar 1, Molly B El Alam 1, Erica J Lynn 1, Tatiana V Karpinets 2, Timothy Harris 1, David Lo 1, Kyoko Yoshida-Court 1, Tatiana Cisneros Napravnik 1, Julie Sammouri 1, Daniel Lin 1, Lauren M Andring 1, Julianna Bronk 1, Xiaogang Wu 2, Travis T Sims 3, Geena Mathew 1, Kathleen M Schmeler 3, Patricia J Eifel 1, Anuja Jhingran 1, Lilie L Lin 1, Melissa M Joyner 1, Jianhua Zhang 2, Andrew Futreal 2, Ann H Klopp 1, Lauren E Colbert 4;
1 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
3 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
4 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: lcolbert@mdanderson.org.
The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis
de Sauvage MA, at al.
neuro-oncology
December 2023
Authors and Affiliates
Magali A de Sauvage 1,2, Consuelo Torrini 1, Edwin Nieblas-Bedolla 1, Elizabeth Summers 1, Emily Sullivan 1, Britney S Zhang 1, Emily Batchelor 1, Braxton Marion 1, Erika Yamazawa 1, Samuel C Markson 3,4, Hiroaki Wakimoto 1, Naema Nayyar 1, Priscilla Brastianos 1,5;
1 Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
2 University of Utah School of Medicine, Salt Lake City, UT, USA.
3 Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
4 Broad Institute of MIT and Harvard, Cambridge, MA, USA.
5 Division of Hematology/Oncology and Neuro-Oncology, Department of Medicine & Neurology, Massachusetts General Hospital. Boston, MA.
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
Nielsen M, et al.
OncoImmunology
December 2023
Authors and Affiliates
Morten Nielsen 1, Tine Monberg 1, Vibeke Sundvold 2, Benedetta Albieri 1, Dorrit Hovgaard 3, Michael Mørk Petersen 3, Anders Krarup-Hansen 4, Özcan Met 1 5, Ketil Camilio 2, Trevor Clancy 6, Richard Stratford 6, Baldur Sveinbjornsson 2, Øystein Rekdal 2, Niels Junker 4, Inge Marie Svane 1;
1 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
2 Lytix Biopharma, Oslo, Norway.
3 Department of Orthopedic Surgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
4 Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark.
5 Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
6 NEC Oncoimmunity AS, Oslo, Norway.
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Matsubara N, et al.
December 2023
Authors and Affiliates
Nobuaki Matsubara 1, Shota Kusuhara 2, Noboru Yamamoto 3, Kazuki Sudo 3, Masahiko Yanagita 4,5, Kosho Murayama 6, Hisashi Kawasumi 4, Deanna L Russell 7, Da Yin 8, Toshio Shimizu 3,9;
1 Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nmatsuba@east.ncc.go.jp.
2 Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
3 Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
4 Research & Development, AstraZeneca K.K., Tokyo, Japan.
5 Oncology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
6 Research & Development, AstraZeneca K.K., Osaka, Japan.
7 Translational Medicine, Early Oncology, Oncology R&D, AstraZeneca Pharmaceuticals, Boston, MA, USA.
8 Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.
9 Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Graduate School of Medicine, Wakayama Medical University Hospital, Wakayama, Japan.
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
Yossef R, et al.
Cancer Cell
December 2023
Authors and Affiliates
Rami Yossef 1, Sri Krishna 2, Sivasish Sindiri 3, Frank J Lowery 3, Amy R Copeland 3, Jared J Gartner 3, Maria R Parkhurst 3, Neilesh B Parikh 3, Kyle J Hitscherich 3, Shoshana T Levi 3, Praveen D Chatani 3, Nikolaos Zacharakis 3, Noam Levin 3, Nolan R Vale 3, Shirley K Nah 3, Aaron Dinerman 3, Victoria K Hill 3, Satyajit Ray 3, Alakesh Bera 3, Lior Levy 3, Li Jia 4, Michael C Kelly 5, Stephanie L Goff 3, Paul F Robbins 3, Steven A Rosenberg 6;
1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: yosef.rami@gmail.com.
2 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: sri.krishna@nih.gov.
3 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
4 National Institutes of Health Library, National Institutes of Health, Bethesda, MD 20892, USA.
5 Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, MD 20892, USA.
6 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: sar@nih.gov.